Street Analysts View On K2M Group Holdings, Inc. (KTWO), Esperion Therapeutics, Inc. (ESPR)

K2M Group Holdings, Inc. (NASDAQ:KTWO) notched a -3.71% intraday decline moving at $18.93. When the opening bell rang, the price was $19.63. The number of shares that were traded during the day was 0.33 million, which corresponds to its 3-month volume average of 0.5 million shares a day.

K2M Group Holdings, Inc. (KTWO) Analyst Opinion

K2M Group Holdings, Inc. has a consensus outperform rating from 10 Wall Street analysts, and the number of shares currently sold short amount to at least 9.27% of shares outstanding. The stock sank -0.84% last month and is down -5.54 this year. Wall Street is only getting more bullish on the stock, with 10 of analysts who cover KTWO having a buy-equivalent rating. Analysts have placed a $23.33 price target on K2M Group Holdings, Inc., suggesting a 23.24% gain from recent close. It’s currently trading about -27.16% below its 52-week high.

K2M Group Holdings, Inc. Earnings Surprise

K2M Group Holdings, Inc. (KTWO) failed to surprise the stock market in its last reported earnings when it earned -$0.2 a piece versus the consensus-estimated -$0.19. Its revenue totaled $66.04 million up 0.53% from the previous quarter.

K2M Group Holdings, Inc. (NASDAQ:KTWO) Intraday View

This stock (KTWO) is ahead of its 52-week low with 9.87%. Its last month’s stock price volatility remained 3.33% which for the week stands at 3.74%. The share price has moved backward from its 20 days moving average, trading at a distance of -0.37% and stays -4.07% away from its 50 days moving average. Over the last five days, shares have faced -2.27% losses and now is down -12.39% since hitting its 200-day moving average of $21.98. K2M Group Holdings, Inc. (KTWO) has made its way to a 12-month decline of -0.53%.

Turning to Esperion Therapeutics, Inc. (NASDAQ:ESPR), its shares were trading at $63.89 a gain of $2.38, on the trading floor. The stock, after opening at $61.45, touched a high of $65.2 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.9. Esperion Therapeutics, Inc. has 6 buy ratings, 2 holds and 0 sells even after the stock climbed 3.55% from its high of $61.70 to a $1.62 billion market value through last close.

Esperion Therapeutics, Inc. (ESPR) Consensus Price Target

The company’s consensus rating on Reuter’s scale remained unchanged from 1.64 to 1.64 during a month. Analysts set a 12-month price target of $65.75 a share. The target implies a 2.91% spike from where the shares are currently trading. Also, the current price highlights a discount of 56.52% to analysts’ high consensus price target.

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Intraday Trading

The counter witnessed a trading volume of 0.72 million shares versus an average volume of 0.51 million shares during last trading session. Its last month’s stock price volatility remained 5.31% which for the week approaches 5.45%. The lowest price the stock reached in the last trading day was $61.02 and compares with the $10.30 52-week low. The stock recovered 520.29% since its low point and has performed 410.3% year-to-date.

Previous articleAnalysts Are Gushing Over Envision Healthcare Corporation (EVHC), Canadian Natural Resources Limited (CNQ)
Next articleAnalyst Commentary On Celsion Corporation (CLSN), Abraxas Petroleum Corporation (AXAS)